At TVT 2022, there was debate whether CT imaging is needed for preplanning LAA procedures, and several new devices in development were discussed.

As a MEDCAC advisor, American Society of Echocardiography past president Jonathan Lindner, MD, will help decide whether services and supplies are reasonable and necessary under Medicare.

Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed.

Researchers compared the new-look drug coated balloon with an uncoated balloon, publishing their findings in JACC: Cardiovascular Interventions.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties. 

It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why.